Revolutionizing High-Throughput Drug Screening With AI and Organoids
In this Technology Networks article, Molecular Devices’ Automation and Customization Commercial Manager Daniel DiSepio, PhD, discusses the evolution of high-throughput drug screening (HTS) on organoids in drug discovery, highlighting the shift from traditional methods to a more intelligent, computational approach facilitated by artificial intelligence (AI).